RMC-9805-305: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)

Disease Sites:

Pancreatic

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic, Mol. targeted/Immunotherapy/Biologics

Drugs:

5-FU (Fluorouracil), Gemcitabine, Irinotecan, Leucovorin, Nab-Paclitaxel, Oxaliplatin, zoldonrasib

Principal Investigator(s):

Cardin, Dana

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-29-2026

Trial Type:

Treatment

Protocol ID:

VICCGI26032

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available